← Back to Search

Behavioural Intervention

Executive Function and CBT Skills Training for Schizophrenia (E-CBSST Trial)

N/A
Recruiting
Led By Eric Granholm, PhD
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 60 years or older
Willing and able to speak English
Must not have
Meets criteria for a cognitive disorder or for a neurological or other medical disorder affecting the ability to participate in Executive Function Training or CBSST
Meets diagnostic criteria for bipolar disorder, current major depressive episode, or substance abuse or dependence within the six months prior to the baseline assessment except for caffeine or nicotine
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, end of executive function training (week 2), mid-trial (week 11), end-trial (week 20)
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test a combination of two types of training, Executive Function Training and Cognitive-Behavioral Skills Training, to see if it is effective in improving social skills. The goal is to

Who is the study for?
This trial is for individuals with schizophrenia, psychosis, or schizoaffective disorder. Participants should be interested in a new therapy that combines cognitive and behavioral skills training with exercises to improve thinking and decision-making.
What is being tested?
The study tests E-CBSST, which blends Executive Function Training (to enhance thinking and decision-making) with Cognitive-Behavioral Skills Training (for social skills). It aims to see if this can significantly improve daily functioning.
What are the potential side effects?
Since E-CBSST is a non-medical intervention focusing on training and skill development, it may not have typical drug side effects. However, participants might experience fatigue or emotional discomfort during the sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.
Select...
I can speak and understand English.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition that affects my ability to participate in specific brain training programs.
Select...
I have been diagnosed with bipolar disorder, depression, or substance abuse in the last 6 months.
Select...
I have not had electroconvulsive therapy in the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, end of executive function training (week 2), mid-trial (week 11), end-trial (week 20)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, end of executive function training (week 2), mid-trial (week 11), end-trial (week 20) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comprehensive Modules Test
Independent Living Skills Survey
Secondary study objectives
Birchwood Social Functioning Scale
Brief Assessment of Cognition in Schizophrenia
Clinical Assessment Interview for Negative Symptoms
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: E-CBSSTExperimental Treatment1 Intervention
E-CBSST is the experimental arm in this study.

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthOTHER
372 Previous Clinical Trials
83,298 Total Patients Enrolled
59 Trials studying Schizophrenia
4,261 Patients Enrolled for Schizophrenia
University of California, San DiegoLead Sponsor
1,180 Previous Clinical Trials
1,574,997 Total Patients Enrolled
28 Trials studying Schizophrenia
5,874 Patients Enrolled for Schizophrenia
Eric Granholm, PhDPrincipal InvestigatorUniversity of California, San Diego
3 Previous Clinical Trials
288 Total Patients Enrolled
3 Trials studying Schizophrenia
288 Patients Enrolled for Schizophrenia
~30 spots leftby Nov 2025